预约演示
更新于：2026-03-18
Aceclofenac
醋氯芬酸
更新于：2026-03-18
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 西班牙 (1993-05-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H13Cl2NO4 |
InChIKeyMNIPYSSQXLZQLJ-UHFFFAOYSA-N |
CAS号89796-99-6 |
关联
48
项与 醋氯芬酸 相关的临床试验CTRI/2025/07/090751
COMPARING HERBAL ANALGESIC (PYROCID) TO ACECLOFENAC FOR POSTOPERATIVE PAIN MANAGEMENT AFTER TEETH EXTRACTION - nil
ISRCTN16167924
Bioequivalence study of a new Aceclofenac 100 mg film-coated tablets formulation versus Gladio® 100 mg film-coated tablets formulation in healthy volunteers
CTRI/2025/04/085094
A Randomized, Multicenter, Comparative, Open label, Phase-IV study to evaluate safety and efficacy of the 3-Drug-Fixed Dose Combination Tablet of Paracetamol 325 mg, Chlorzoxazone 250 mg and Aceclofenac 100 mg in comparison with Paracetamol 325 mg and Aceclofenac 100 mg Tablet administered BID in adult patients with Acute Musculoskeletal Pain Associated with Spasm. - Nil
100 项与 醋氯芬酸 相关的临床结果
登录后查看更多信息
100 项与 醋氯芬酸 相关的转化医学
登录后查看更多信息
100 项与 醋氯芬酸 相关的专利（医药）
登录后查看更多信息
971
项与 醋氯芬酸 相关的文献（医药）2026-05-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
Mechanistic insights into carbon dot–aceclofenac interactions: An experimental and theoretical approach
Article
作者: Subramani, Thangavel ; Krishnasamy, Karthik
In this study, carbon dots (CDs) were synthesized from Tribulus terrestris leaves (TTLF) through a greener, chemical-free method, underscoring environmental sustainability and their biocompatibility. Aceclofenac (ACE), a widely used nonsteroidal anti-inflammatory drug (NSAID), was selected to investigate its interaction with CDs and to explore the potential of CDs as nanocarriers for drug delivery. The AC complex interaction was examined using a multi-level computational framework complemented by FT-IR and UV-Vis experimental data. These analyses provide detailed mechanistic insights into non-covalent interactions, electronic perturbations, hydrogen bonding, charge transfer, and stabilization mechanisms in the AC complex. These findings offer a foundational mechanistic and analytical understanding that can guide future studies on ACE delivery and formulation optimization, highlighting the potential of green CDs as sustainable nanocarriers for therapeutic agents.
2026-03-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Population pharmacokinetic model-based IVIVC incorporating active metabolite kinetics: Application to aceclofenac sustained-release formulations
Article
作者: Shin, Soyoung ; Kim, Taehyung ; Shin, Beom Soo ; Kim, Tae Hwan
This study aimed to establish a population pharmacokinetic model-based in vitro-in vivo correlation (IVIVC) for aceclofenac sustained-release (SR) formulations to predict plasma concentrations of both parent drug and active metabolite, diclofenac. Three SR formulations containing 200 mg aceclofenac with different drug release rates were prepared and characterized for in vitro dissolution using the paddle method. In vivo pharmacokinetics were evaluated in beagle dogs (n = 4 per formulation) following oral administration. Plasma concentrations of aceclofenac and diclofenac were simultaneously quantified using a validated liquid chromatography-tandem mass spectrometry method. A population pharmacokinetic model was developed incorporating formulation-dependent Michaelis-Menten dissolution kinetics, time-dependent absorption, and metabolite formation. In vivo dissolution rates estimated from the model were correlated with in vitro dissolution rates to establish a level A IVIVC. An independent formulation was used for external validation. The resulting model successfully described plasma concentration-time profiles of both compounds across all formulations, with logarithmic correlation between in vitro and in vivo dissolution rates demonstrating strong predictability (R2 = 0.96). For the external validation formulation, Cmax prediction errors were 1.32% and 1.50% for aceclofenac and diclofenac, respectively, while AUC prediction errors were 16.49% and 2.39%. This study successfully established a population pharmacokinetic model-based IVIVC that predicts the pharmacokinetics of both parent drug and active metabolite from in vitro dissolution data. This approach provides a practical framework for developing SR formulations of drugs with active metabolites.
2026-02-01JOURNAL OF PHARMACEUTICAL SCIENCES
Thermosensitive in-situ gel based on halloysite nanotube/chitosan for site-specific delivery of aceclofenac
Article
作者: Romero, Eder Lilia ; Kumar, Mohit ; Randhawa, Jaspreet Kaur ; Chen, Wen-Cheng ; Thomas, Sabu ; Mahmood, Syed ; Singha, Souvik ; Chellathurai, Melbha Starlin ; Ghosal, Kajal
Periodontitis, a severe and chronic inflammatory gum disease, necessitates the development of advanced drug delivery strategies due to the limitations of conventional therapies, such as rapid drug clearance and inadequate site-specific retention. This study addresses these challenges by formulating and evaluating a novel aceclofenac-loaded halloysite nanotube (HNT) In-situ gel designed for effective local treatment of periodontitis. Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID) known for its potent anti-inflammatory action and reduced gastrointestinal side effects, was encapsulated within HNTs to achieve sustained drug release and enhanced therapeutic efficacy. These drug-loaded HNTs were subsequently incorporated into a thermosensitive In-situ gelling system composed of medium molecular weight chitosan, sodium bicarbonate, and sodium β-glycerophosphate. This gel formulation demonstrated favourable properties, including syringeability, swelling capacity, and temperature-responsive gelation at physiological conditions. The comprehensive characterization techniques such as FTIR, SEM, TEM, PXRD, DSC/TGA, confirmed successful drug encapsulation, structural stability, and uniform distribution within the gel matrix. The in vitro release studies revealed a sustained drug release profile, following zero-order and Korsmeyer-Peppas kinetics, indicative of a Super Case-II transport mechanism. This novel, thermoresponsive local drug delivery system shows strong potential to improve the clinical management of periodontitis by providing prolonged therapeutic action, targeted delivery, and improved patient compliance.
100 项与 醋氯芬酸 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 平滑肌瘤 | 欧盟 | 2018-08-27 | |
| 平滑肌瘤 | 冰岛 | 2018-08-27 | |
| 平滑肌瘤 | 列支敦士登 | 2018-08-27 | |
| 平滑肌瘤 | 挪威 | 2018-08-27 | |
| 类风湿关节炎 | 英国 | 1996-04-08 | |
| 强直性脊柱炎 | 英国 | 1996-03-24 | |
| 骨关节炎 | 英国 | 1996-03-24 | |
| 风湿性疾病 | 西班牙 | - | 1993-05-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 143 | 願憲艱醖鏇蓋糧餘壓簾(鑰淵餘窪鏇鹹獵廠廠築) = 淵鹽鹹構糧餘鹹簾憲願 憲蓋淵膚觸齋構憲鹽壓 (憲獵網鹽憲簾選築築壓, 14.17) 更多 | - | 2013-06-24 | |||
N/A | - | 觸廠鬱壓鏇齋選廠鬱鹹(範鹽製鹹廠蓋膚淵鬱範) = 鹹淵艱餘夢齋築積簾膚 積衊壓鹽憲襯簾鑰廠構 (艱鏇顧顧壓窪簾餘廠膚 ) 更多 | 积极 | 2002-06-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用